Cyberonics, Inc. (CYBX) reported second quarter fiscal 2010 earnings per share of 32 cents, beating the Zacks Consensus Estimate of 20 cents and the year-ago earnings of 14 cents.   Sales Net sales in the reported quarter increased 13.0% year over year to $40.7 million. Of this, net product sales in the domestic market increased 15.1% year over year to $33.5 million. Growth was due to higher average selling prices (ASPs) and sales volume. ASPs and sales volume increased 10.0% and 5.1% year over year, respectively.   International sales increased 4.3% year over year to $6.8 million. Growth can be attributed to higher sales volume made through distributors, which was partly offset by lower ASPs. Licensing revenues constituted the remaining $0.4 million. Margins Gross margin increased 180 basis points (bps) year over year to 87.4%. Growth can be primarily attributed to higher sales volume, greater manufacturing efficiencies ...

For Immediate Release

Chicago, IL – October 23, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Wal-Mart (WMT), Capital One (COF), Merck (MRK), GlaxoSmithKline (GSK) and Schering Plough (SGP).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Thursday’s AnalystBlog:

New Jobless Claims Up

This long-term unemployment is an insidious problem for the economy. People who are out of work for just a few weeks really don't have to cut back on their consumption that much, especially if they feel confident that they will have a new job in a short time.

People

...

Merck’s (MRK) earnings for the third quarter came in at 90 cents per share, which was ahead of the Zacks Consensus Estimate of 82 cents, driven by continued growth of its key products and strict cost management. The company reported revenues of $6 billion, up 2% from the same period in 2008. Revenue would have higher, but for the unfavorable foreign exchange movement, which affected global sales by 3%. Weaker-than-expected sales of Gardasil were offset by significantly stronger-than-anticipated Singulair revenues. Although the US Food and Drug Administration (FDA) asked for additional precautions regarding the risks associated with the use of Merck’s lead product Singulair (as well as other leukotriene inhibitors), including suicide and depression, the drug recorded an increase of 5% compared to the third quarter of 2008. Gardasil, Merck’s cervical cancer vaccine, recorded yet another quarter of lower sales. The company recorded $311 million in ...

Cyberonics, Inc. (CYBX) entered into two collaboration agreements in the field of EEG-based seizure detection technology to bolster its leadership position in epilepsy. The collaborations are with NeuroVista Corporation and the Massachusetts Institute of Technology.  The License Agreement with NeuroVista Corporation entered on Oct 1, 2009 provides Cyberonics with access to a wide range of technology and patents in exchange for payments extending through Apr 2011. Details regarding the payments have not yet been disclosed.  The NeuroVista technology includes an algorithm for seizure detection, a rechargeable battery system, wireless communication, and an implantable lead and will help Cyberonics accelerate its development of an implantable pulse generator. NeuroVista Corporation is an early-stage medical device company pioneering new technologies in the management and treatment of epilepsy, a central nervous system disorder characterized by loss of consciousness and convulsions.  In early 2009, Cyberonics entered into an Exclusive Patent ...

Results from Arena’s (ARNA) phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated to 7.9% and 8.2% mean absolute weight loss. The placebo was 3.9% and 3.4% in each trial, respectively, putting the mean placebo-adjusted weight loss for each trial at 4.0% and 4.8%. Total categorical weight loss for the completer analysis was 63.2% in BLOSSOM and 66.4% in BLOOM, vs. 34.9% and 32.1% for the placebo. Per the FDA draft guidance: “A product can be considered effective for weight management if after one year of treatment either of the following occurs: (1) the difference in mean weight loss between the active-product and placebo-treated groups is at least 5% and the difference is statistically significant, or (2) the proportion of subjects who lose ...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

DrStockPick.com Watch List!

My Picks for Wednesday September 16, 2009, are:

**************************************************************

MVIS, Microvision, Inc.

MVIS is a global leader in innovative ultra-miniature projection display and image capture products for mobility applications

Today was the commercial introduction of the world’s first laser-based pico projector, called SHOW WX™, based on its proprietary PicoP® display engine technology.

The MVIS pico projector uses the revolutionary laser-based PicoP display engine that delivers large, colorful, bright, and vivid images that are always in focus, regardless of projection distance. The accessory product is a simple plug-n-play pico projector for people on-the-go who

...

Adeona Pharmaceuticals, Inc.

(Public, AMEX:AEN)

StocksHaven Investments takes a look at Adeona Pharmaceuticals, Inc. which currently has three blockbuster drugs in phase III, and are coming close to NDA status. The first being Trimesta, which tackles Multiple Sclerosis (MS) and Post-partum Depression. Secondly, Zinthionein, a product seeking treatment for Age Related Macular Degeneration (AMD). Lastly, Oral dnaJP1 which is an immunotherapy for rheumatoid arthritis (RA) patients. If these products aren’t enough to entice your way into purchasing this stock, take a look at the recent $5 million dollar cash infusion from the National Multiple Sclerosis Society (NMSS), billions of dollars in product market potential, purchasing of Hartlab LLC, an independent Chicago-area CLIA-certified clinical reference laboratory, an experienced management team that will have you feeling like a kid in a candy store, and to

...

Cannabis Science Inc., an emerging pharmaceutical cannabis company, was pleased to announce this morning that it has signed an agreement with Leading Points Corp. to represent its products, services and initiatives to various government and military agencies. Leading Points is led by its founder who retains 20 years of service as an active duty commissioned officer to establish and secure mutually beneficial relationships between its clients and the military and government markets.

Leading Points Corporation, Founder and President, Retired Lieutenant Colonel Kevin Sullivan, stated, “We are in the process of rolling out a phased strategy that initially calls for Leading Points Corporation to work with key decision makers in the 14 U.S. States where the legislatures have approved the use of whole cannabis, the natural product, for medicinal use. Next, we will represent the company in respect to a number of federal initiatives and to insure that they are positioned

...

PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com News Report!

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Appoints Medical Director

-Lourdes R. Bosquez, MD, PA Appointed New Medical Director for PWRM-

 

Friday August 28, 2009

************************************************************** Power3 Medical Products, Inc. Appoints Medical Director

Lourdes R. Bosquez, MD, PA Appointed New Medical Director for Power3 Medical Products, Inc.

Woodlands, TX, - (CRWENEWSWIRE ) Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that Lourdes R. Bosquez, MD, PA, was appointed Medical Director of the Company.

Power3 Medical Products, Inc., a biotechnology company with diagnostic products for Alzheimer’s disease, Parkinson’s disease, Breast Cancer and other diseases, has secured the

...

PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com News Report!

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Appoints Medical Director

-Lourdes R. Bosquez, MD, PA Appointed New Medical Director for PWRM-

 

Thursday August 27, 2009

************************************************************** Power3 Medical Products, Inc. Appoints Medical Director

Lourdes R. Bosquez, MD, PA Appointed New Medical Director for Power3 Medical Products, Inc.

Woodlands, TX, - (CRWENEWSWIRE ) Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that Lourdes R. Bosquez, MD, PA, was appointed Medical Director of the Company.

Power3 Medical Products, Inc., a biotechnology company with diagnostic products for Alzheimer’s disease, Parkinson’s disease, Breast Cancer and other diseases, has secured the

...